復星醫藥(02196.HK):全力確保新冠口服藥「阿茲夫定」供應 已覆蓋內地主要醫療機構
《澎湃新聞》報道,復星醫藥(02196.HK)總裁文德鏞表示,目前新冠抗病毒藥物阿茲夫定片已在內地31個省、自治區、直轄市完成醫保掛網,掛網價格為每瓶270元人民幣(每瓶35片,每片1毫克),已覆蓋內地各地主要醫療機構,包括二級以上醫院和基層醫療衛生機構等。同時,阿茲夫定已開通互聯網醫院問診處方平台渠道,方便民眾就醫用藥。
文德鏞透露,目前阿茲夫定保供已成為集團內部「一號任務」,包括生產負責人、質量人員、供應鏈人員等均被抽調到一線,確保阿茲夫定的產品供應能在第一時間滿足需求。
此外,保障用藥安全也是復星醫藥的首要目標。文德鏞介紹,作為國內首個治療新冠病毒感染的小分子口服藥,阿茲夫定已經在菲律賓等國家開展暴露後預防新冠感染臨床試驗,在全國各地也開展多個上市後的真實數據研究。阿茲夫定的多個國內外臨床研究結果也證明其抗新冠病毒的療效和安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.